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Abstract
Objective—To assess the efficacy and safety of a 24-week course of abatacept in the treatment
of active lupus nephritis. An additional exploratory objective was to assess the potential of
abatacept to induce ‘clinical tolerance’, defined as sustained clinical quiescence of lupus nephritis
after discontinuation of immunosuppressive therapy.
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Methods—Patients (n=134) with active lupus nephritis were studied in a randomized, doubleblind phase II add-on trial in which they received either abatacept or placebo in conjunction with
the Euro-Lupus regimen of low-dose cyclophosphamide followed by azathioprine. The primary
efficacy outcome was the frequency of complete response (CR) at week 24. Thereafter, patients
who met either complete or partial response criteria continued blinded treatment through week 52.
During this phase of the study, subjects in the abatacept treatment group who had achieved CR
status at week 24 discontinued immunosuppressive therapy other than prednisone (10 mg/d).

Author Manuscript

Results—There were no statistically significant differences between groups with respect to the
primary outcome or any of the secondary outcomes, including measures of safety. Thirty-three
percent of subjects in the treatment group and 31% of subjects in the control group achieved CR
status at week 24. Fifty percent of subjects in the treatment group who met CR criteria and
therefore discontinued immunosuppressive therapy at week 24 maintained their CR status through
week 52.
Conclusion—The addition of abatacept to a regimen of cyclophosphamide followed by
azathioprine did not improve the outcome of lupus nephritis at either 24 or 52 weeks. No
worrisome safety signals were encountered.

Author Manuscript

There are no consistently safe and effective treatments for lupus nephritis. Induction therapy
for active nephritis typically consists of moderate-to-high dose glucocorticoids (GC)
combined with an additional potent immunosuppressive drug, followed by maintenance
therapy involving long-term sustained immune suppression [1]. Despite this aggressive
approach to treatment, many patients continue with active nephritis and/or recurrent flares,
and all patients are exposed to the risks of therapy, including the potential for fatal
complications.
For several decades, the standard of care for active lupus nephritis consisted of monthly
intravenous pulses of cyclophosphamide (CTX) for at least six months, with a target of
achieving modest depression of circulating leukocyte counts between doses. This approach
had emerged from a relatively small trial that compared high-dose GC alone with several
alternative regimens consisting of GC in combination with other immunosuppressive agents
[2]. Progression to renal failure occurred most often among patients who received GC alone.
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Although the trial did not distinguish convincingly among the various combination
regimens, the community adopted pulse CTX as the preferred approach. In recent years, two
other approaches have been compared to high-dose pulse CTX and appear to have
equivalent efficacy. One approach is based on the Euro-Lupus Nephritis Trial (ELNT). It
utilizes a shorter and less intense regimen of CTX followed by maintenance therapy with
azathioprine (AZA) [3, 4]. The other approach utilizes mycophenolate mofetil (MMF)
instead of pulse CTX [5–8]. There is reason to believe that these regimens may be safer than
high-dose pulse CTX.
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Against this background, there has been great hope that the advent of targeted biologic
therapies would lead to breakthroughs in the treatment of lupus nephritis. Thus far, however,
these hopes have not been realized [1, 9]. CTLA4Ig is among the biologic interventions that
have generated great interest. The rationale for testing CTLA4Ig in lupus nephritis is very
strong. CTLA4Ig blocks binding of antigen-presenting cells to CD28 on T cells, thereby
inhibiting activation of primary T-dependent immune responses [10]. CTLA4Ig may also
have direct inhibitory effects on the B cell lineage, as CD28 is expressed on plasma cells;
whether CD28 engagement mediates positive or negative regulation remains an area of
controversy [11–13]. In murine models for SLE, CTLA4Ig acts synergistically with CTX to
arrest lupus nephritis [14, 15]. In humans, CTLA4Ig (abatacept) is effective in the treatment
of rheumatoid arthritis [16, 17]. Moreover, a post-hoc analysis of a large trial of abatacept
(ABA) in people with lupus nephritis strongly suggested clinical benefit [18]. Finally, a
recent study of patients with focal segmental glomerulosclerosis showed that treatment with
ABA induced disease remission, apparently by binding to CD80 on renal podocytes [19].
Taken together, these observations provide a strong foundation for postulating that ABA
may be effective in people with lupus nephritis.
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PATIENTS AND METHODS
Study design and treatment protocol
The ACCESS trial was a 1:1 randomized, double-blind, controlled phase II multicenter trial
of ABA vs placebo on a background of treatment with GC plus CTX followed by AZA in
patients with active lupus nephritis. The trial consisted of two phases. In the first phase,
patients with active lupus nephritis were randomized to receive monthly infusions of either
placebo or ABA. Subjects in both groups also received six biweekly pulses of CTX followed
by oral AZA based on the ELNT regimen [3] as well as a tapering regimen of oral GC. The
primary outcome measure was the proportion of subjects who achieved a complete response
(CR) at week 24.

Author Manuscript

Treatment was initiated with monthly infusions of either placebo or ABA at doses that were
adjusted for body weight according to the ABA dose that is recommended for rheumatoid
arthritis (<60 kg, 500 mg; 60–100 kg, 750 mg; >100 kg, 1 gram). All patients received six
intravenous pulses of 500 mg of CTX at two-week intervals followed by oral AZA at 2
mg/kg/d based on the ELNT regimen. This control regimen differed slightly from the
original ELNT regimen with respect to the approach to GC treatment. Unlike the ELNT
trial, the ACCESS trial did not employ an initial intravenous pulse of GC, but rather left that
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decision to the site investigator’s discretion. Oral GC treatment was begun at 60 mg/d for
two weeks in all subjects, followed by a prescribed taper to 10 mg/d over the next 10 weeks.
The second phase of the trial (weeks 24–52) was exploratory and was intended to generate
preliminary data regarding the potential of ABA to restore self-tolerance, defined as
sustained quiescence of nephritis off immunosuppressive therapy. In this phase, patients
who met CR criteria on ABA at week 24 then discontinued immunosuppression with ABA
and AZA at week 28 and continued only on prednisone 10 mg/d. Patients who had achieved
only a partial response on ABA continued therapy with monthly infusions of ABA and daily
oral AZA. In the control group, patients who had achieved either a complete or partial
response continued AZA. Patients who were non-responders at week 24 discontinued the
trial at that point. Institutional review boards at all sites approved the study design, and all
subjects provided written informed consent.
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Study subjects
Eligible subjects were 16 years of age or older. They fulfilled the American College of
Rheumatology (ACR) criteria for SLE, and they had a positive antinuclear antibody (ANA)
and/or a positive anti-double-stranded DNA antibody test at study entry. All subjects had
active lupus nephritis, defined by: (a) kidney biopsy documentation within the last 12
months of International Society of Nephrology/Renal Pathology Society (ISN/RPS)
proliferative nephritis (class III or class IV, with or without features of class V); and (b)
urine protein-to-creatinine ratio (UPCR) >1. Overall, 137 subjects were enrolled, of whom
134 met entry criteria and comprised the intent-to-treat population for the efficacy analysis.
Study subjects came from 19 sites in the United States and two sites in Mexico. Enrollment
began in November 2008 and concluded in June 2012.

Author Manuscript

Study endpoints and assessments
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The primary efficacy endpoint was the proportion of subjects who achieved a complete renal
response (CR) at week 24. CR was defined as all of the following: (i) UPCR <0.5 based on a
24-hour urine collection; (ii) serum creatinine ≤1.2 mg/dL or ≤125% of baseline; and (iii)
adherence to the prednisone taper to 10 mg/d by week 12. Prospectively defined secondary
efficacy endpoints included: (i) the proportion of subjects who achieved a partial response
(PR) at week 24, defined by the same criteria as the CR definition except that the UPCR
component of the PR definition required only a 50% improvement from baseline rather than
a decline to <0.5; (ii) the proportion of subjects who met the UPCR and GC criteria for CR
at week 24; (iii) the proportion of subjects who met the UPCR and GC criteria for PR at
week 24; (iv) the proportion of subjects who met either CR or PR criteria at week 52; (v) the
proportion of subjects who achieved CR status at week 24 and who maintained that response
to week 52; (vi) time to CR or PR; and (vii) lupus disease activity as reflected by reduction
of anti-dsDNA antibodies, resolution of hypocomplementemia (C3 or C4), patient global
assessment, the 36-Item Short-Form Health Survey (SF36) score [20], and the British Isles
Lupus Assessment Group (BILAG)-2004 score [21]. Secondary efficacy endpoints also
included frequency of lupus flares, either renal or non-renal. For subjects who had achieved
CR status at week 12 or any time thereafter, a renal flare was defined as recurrence of
proteinuria >1 gm/24 hours. For all others, a renal flare was defined as either of the
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following: (i) serum creatinine at least 25% higher than baseline or above the upper limit of
normal, plus proteinuria at least 75% of baseline; or (ii) doubling of UPCR compared with
the lowest previous value. A non-renal flare was defined by the BILAG-2004 guidelines as
any new ‘A’ finding in a nonrenal organ system. Adverse events (AEs) were graded
according to the National Cancer Institute Common Terminology Criteria for Adverse
Events (version 3.0).
Power/sample size
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Using data from the ELNT [3, 4], the statistical analysis plan was based on the assumption
that the proportion of CR outcomes at week 24 in the control group would be 20%. Our goal
was to detect a 30% increase in the CR rate in the ABA group (50% compared to 20%).
Subjects dropping out of the study prior to week 24 were handled as clinical response
failures for the primary analysis. As such, after adjusting for an expected 10% dropout rate
equally distributed to the two groups, this difference corresponds to an expectation of 45%
CR in the ABA group and 18% CR in the control group. To detect this 27% difference at
90% power using a two-sided Fisher’s exact test at the 0.05 level of significance, a sample
size of 67 subjects per group was required.

RESULTS
Study population

Author Manuscript

Sixty-eight subjects were randomized to the control group, and 66 subjects were randomized
to the ABA treatment group (Figure 1). Baseline characteristics were well-matched between
treatment groups (Table 1). Approximately 90% of subjects were women. The mean age at
entry was 32 years. The study population was racially and ethnically diverse, including 39%
African American subjects and 40% Hispanic or Mestizo subjects. Thirty-four percent of the
subjects had ISN/RPS LN class III with or without features of class V, and 66% had class IV
with or without features of class V. Forty-six percent of subjects in the control group and
41% of subjects in the treatment group entered the trial with UPCR>3. Seventy-one percent
of subjects in each group had duration of nephritis <1 year. At the time of study entry, 60%
of subjects were receiving an antimalarial drug and 73% of subjects were receiving either an
angiotensin-converting-enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB).
The use of these agents was comparable between the two treatment groups.
Primary Outcome Measure

Author Manuscript

There was no significant difference in the CR rate at week 24 between the ABA and control
groups (Figure 2a) (Fisher’s exact test). CRs occurred in 21/68 (31%) of control subjects and
22/66 (33%) of ABA-treated subjects.
Secondary Efficacy Outcome Measures
The frequency of total responses (complete or partial) was identical in the two groups at
59% (Figure 2b). There also were no statistically significant differences in any of the other
pre-specified secondary outcome measures (Table 2), including: (i) the proportion of
subjects who met the proteinuria and prednisone requirements for CR or PR; (ii) the
proportion of subjects who had a 75% reduction in anti-dsDNA antibodies; (iii) the
Arthritis Rheumatol. Author manuscript; available in PMC 2015 November 01.
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proportion of subjects with negative anti-dsDNA; (iv) resolution of hypocomplementemia as
measured by C3 or C4 levels; (v) time to CR or PR; (vi) patient global assessment; (vii)
SF-36 physical and mental scores; (viii) BILAG-2004 score, or (ix) frequency of flares. The
mean UPCR at week 24 was 1.1 ± 1.2 in the control group compared to 1.1 ± 1.3 in the
ABA group (p=ns). The CR rate was lowest among Black subjects in the control group
(16% vs 40% among non-Black control subjects), but no such difference was observed in
the ABA group (33% CR in both Black and non-Black subjects) nor were any of the
differences among racial and ethnic groups statistically significant. CR and PR rates were
not significantly different when comparing subjects with recent onset of nephritis (<1 year)
to subjects with a longer history of nephritis (≥1 year) (data not shown).
Safety
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There were no clinically or statistically significant differences between groups at week 24 in
total adverse events, lupus-related adverse events, serious adverse events, serious infectious
adverse events, opportunistic infections, or withdrawals due to adverse events (Table 3).
There was one death, due to sepsis, in the control group.
Outcomes at Week 52
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Forty subjects from the control group and thirty-nine subjects from the ABA group
continued per protocol beyond the primary endpoint at week 24. Their outcomes are shown
in Table 4. According to the protocol, the 22 subjects in the ABA group who met CR criteria
at week 24 discontinued ABA and AZA at week 28 and continued on prednisone alone 10
mg/d thereafter. Eleven of these subjects (50%) maintained CR status through week 52,
compared to 13/21 (62%) subjects in the control group who maintained CR status while
continuing AZA through week 52 (p=ns). One subject in each group deteriorated from CR at
week 24 to PR at week 52. Two subjects in the ABA group and four subjects in the control
group either withdrew due to a renal flare or failed to meet either CR or PR criteria at week
52. One patient in the ABA group withdrew due to a non-renal flare, and several subjects in
each group withdrew for reasons unrelated to lupus or study treatment. Overall, 13 subjects
in the control group withdrew from the trial due to active nephritis, compared to 5 subjects
in the ABA group (Fig. 1).
All subjects who were classified as PR at week 24 continued their immunosuppressive
treatment during weeks 24–52. Again, there were no significant differences between groups.
The most common outcome in both groups was to improve from PR status at week 24 to CR
status at week 52 (Table 4).
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There were no statistically significant differences in any of the secondary outcome measures
at week 52 (not shown). With regard to safety between weeks 24 and 52, there were ten
SAEs (5 in each group), no discontinuations due to infection, and no deaths.

DISCUSSION
This trial did not demonstrate any benefit for ABA when added to a regimen consisting of
low-dose pulse CTX followed by AZA in patients with lupus nephritis. This finding
suggests that ABA may not be effective in lupus nephritis. However, there are alternative
Arthritis Rheumatol. Author manuscript; available in PMC 2015 November 01.
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explanations that might account for the outcome. This trial explored only one dose regimen,
which was based on the dose of ABA that is approved for the treatment of rheumatoid
arthritis. It is possible, therefore, that a higher dose might be required for lupus nephritis.
Background therapy may be important. In this trial, we chose to use CTX as the foundation
for the background regimen, based on studies in murine lupus suggesting potential synergy
between ABA and CTX [14, 15]. By using a low-dose approach to CTX therapy, we may
have used too little to achieve a synergistic benefit. A post-hoc analysis of a prior trial of
ABA in lupus nephritis suggested possible benefit on a background of MMF [18], so
perhaps a combination with MMF would be more effective. Finally, this add-on trial
demonstrated that ABA does not provide additional benefit when superimposed on
background therapy initiated with high-dose GC followed by CTX and AZA. However, it
does not establish whether ABA might demonstrate comparable efficacy in a head-to-head
trial design. In that context, it is even possible that the background GC therapy or the
multiple doses of CTX in this trial interfered with the mechanism of action of ABA. It may
be noteworthy in that respect that the preclinical mouse studies that contributed to the
foundation for this trial did not employ GC at all. Although the alternative explanations for
the trial results are all plausible, it would be a daunting task to put them to the test.
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A unique aspect of this trial was the opportunity it provided to acquire preliminary data on
the impact of discontinuing immunosuppressive therapy in patients who achieve CR status
within 24 weeks. This opportunity resulted from three factors. First, there is a biologic
rationale for postulating that CTLA4Ig might induce tolerance among autoreactive T cells
[10, 22]. Second, studies in mice indicate that the beneficial effect of CTLA4Ig on murine
lupus nephritis persists even after treatment is discontinued [23]. Third, this trial was
supported by the Immune Tolerance Network, which has a mission to evaluate therapies that
have the potential to induce clinical tolerance, defined as quiescence of autoimmune disease
in the absence of ongoing immunosuppressive therapy. This goal is particularly important in
lupus, where it is unknown whether the risks of long-term immunosuppression exceed the
risks of discontinuing therapy in patients who achieve a complete response. There is little
information in the literature to address this issue. One trial demonstrated that continued
immunosuppression with pulse methylprednisolone plus CTX was preferable to reliance on
pulse methylprednisolone alone as maintenance therapy, but that result was based on an
examination of the overall study population and did not focus on the minority of subjects
who had achieved complete responses [24]. Similarly, retrospective analyses of longitudinal
cohorts have demonstrated the benefit of maintenance therapy for the entire cohort, but have
not provided data about the risk:benefit ratio specifically for subjects without evidence of
active disease [25]. A recent report described successful withdrawal of immunosuppressive
therapy from lupus nephritis patients in remission, but in that report the duration of
treatment for lupus nephritis varied between 2.5 and 10 years prior to gradual tapering and
eventual discontinuation of therapy (26). In the ACCESS trial, we discontinued
immunosuppressive therapy in 22 subjects in the ABA treatment group who met CR criteria
at week 24, because those were the subjects in whom the scientific rationale for
discontinuing therapy was strongest. Eleven of those subjects maintained their CR status
through week 52. The 50% success rate at maintaining CR in this group was similar to the
62% (13/21) success rate among subjects in the control group maintained on AZA who met
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CR criteria at week 24. These exploratory findings cannot be interpreted to imply that ABA
contributed to the sustained quiescence, but they raise the possibility that, once a complete
response is achieved, it may be possible to discontinue immunosuppression, monitor patients
closely, and avoid the risks of ongoing immunosuppression. There was no difference
between the groups in the number of subjects who lost their renal response or had a nonrenal flare between weeks 24 and 52 (3/22 complete responders who discontinued
immunosuppressive therapy compared to 4/21 complete responders who continued AZA
maintenance therapy). The number of subjects in this exploratory analysis is small, but the
results suggest that further study is warranted to determine whether maintenance therapy
should be continued after establishment of CR.
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The ACCESS trial provided an important opportunity to explore the effectiveness of the
Euro-Lupus treatment strategy in a racially and ethnically diverse North American
population. Previous studies of this regimen strongly suggested that a less aggressive
approach to pulse CTX might be as effective as, and safer than, the more intense CTX
regimen that has long been the standard of care [3, 4]. However, those studies involved
primarily Northern European lupus patients, of whom most were White patients with
newonset rather than refractory nephritis. Due to the nature of the study population, there
has been a reluctance to generalize those results to other populations, especially Black and
Hispanic populations who tend to have more severe and refractory disease [27–32]. By
succeeding in recruiting a racially and ethnically diverse population of lupus patients that
more closely resembles the overall demographics of lupus, we have been able to show that
the response rates for the Euro-Lupus regimen in this population closely match, or slightly
exceed, the response rates for high-dose CTX or MMF reported from other trials [6, 9],
although the efficacy of this regimen in Blacks warrants further study.
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There have now been two trials of ABA in patients with lupus nephritis. Neither trial
achieved its primary outcome goal. The prior trial employed a control regimen of MMF
rather than CTX/AZA [18]. Although that trial failed to meet its primary endpoint, a posthoc analysis suggested that there may have been efficacy that wasn’t captured by the
prospectively defined endpoint [18]. Therefore, a second large, multicenter international trial
of ABA on a background of MMF is currently underway (NCT01714817). The results of
that trial will provide additional data to determine whether ABA will have a role in the
treatment of lupus nephritis.
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Figure 1.

Treatment assignments and withdrawals in the intention-to-treat population.
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Figure 2.
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Complete response rate (A) and total response rate (complete responses plus partial
responses) (B) at week 24 among control subjects treated with either the Euro-Lupus (EL)
regimen or the EL regimen plus abatacpet (EL+ABA).
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Table 1

Author Manuscript

Patient demographics and baseline characteristics*
Control
(n=68)

Abatacept
(n=66)

32.7 ± 12.0

32.0 ± 10.1

64 (94%)

58 (88%)

  White

33 (49%)

34 (51%)

  Black

25 (37%)

27 (41%)

  Asian

3 (4%)

3 (5%)

  Mixed or Undeclared

7 (10%)

2 (3%)

28 (41%)

25 (38%)

75 ± 23

74 ± 18

  Systolic

133 ± 17

130 ±17

  Diastolic

83 ± 11

79 ± 12

48 (71%)

47 (71%)

  Class III

11

10

  Class IV

24

24

    Segmental

8

10

    Global

16

14

  Class III + V

12

12

  Class IV + V

20

20

  Serum creatinine (mg/dl)

1.3 ± 0.6

1.2 ± 0.7

  Estimated GFR (ml/min/1.73 m2)

58 ± 28

65 ± 36

  24-hour total (gm/d)

4.5 ± 4.0

3.8 ± 3.1

  Protein:creatinine ratio (mg/mg)

4.1 ± 3.4

3.6 ± 2.6

  UPCR >3

31 (46%)

27 (41%)

Serum albumin (g/dl)

2.7 ± 0.7

2.8 ±0.6

  ANA positive (≥1:80)

68 (100%)

66 (100%)

  Anti-dsDNA positive

50 (75%)

49 (75%)

  C3 complement low

44 (70%)

47 (78%)

  C4 complement low

37 (59%)

39 (65%)

45 ± 28

42 ±30

39 ± 10

39 ± 11

Variable
Age (years) – mean±SD
Females
Primary Race

Ethnicity
  Hispanic/Mestizo

Author Manuscript

Weight (kg)
Blood pressure (mm Hg)

Time from onset of lupus nephritis
  <1 year
ISN/RPS** classification

Author Manuscript

Renal function

Urine protein

Serology (at randomization)

Author Manuscript

Patient global assessment
SF-36
  Physical component score
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Variable

Control
(n=68)

Abatacept
(n=66)

  Mental component score

40 ± 13

40 ± 13

*

Except where noted, values are the number (%). Percentages are calculated out of the number of subjects with evaluable data.

**

ISN/RPS – International Society of Nephrology/Renal Pathology Society. Biopsies were read and classified by pathologists at the local sites.
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Table 2

Author Manuscript

Secondary outcome measures at week 24*
Outcome measure

Control

Abatacept

Urinary protein-to-creatinine ratio, mean ± SD

1.1 ± 1.2

1.1 ± 1.3

Disappearance of anti-dsDNA antibody

4/36 (11)

9/38 (24)

Correction of low C3 concentration

11/30 (37)

14/38 (37)

Correction of low C4 concentration

10/25 (40)

17/32 (53)

Total BILAG score, mean ± SD

3.4 ± 1.8

3.8 ± 3.0

Patient’s global assessment, mean ± SD

28 ± 25

18 ± 22

  Physical component score

45.3 ± 11

45.3 ± 11

  Mental component score

46.5 ± 11

45.9 ± 12

3/68 (4.4)

3/66 (4.5)

6/68 (9)

8/66 (12)

    White

14/33 (42)

12/34 (35)

    African American

4/25 (16)

9/27 (33)

    Asian

1/3 (33)

1/3 (33)

    Mixed or undeclared

2/7 (29)

0/2 (0)

SF-36, mean ± SD

Subjects with lupus flares

Author Manuscript

  Renal flare
  Nonrenal flare
Complete response by race/ethnicity
  Race

  Ethnicity
    Hispanic/Mestizo

10/28 (36)

8/25 (32)

    Not Hispanic/Mestizo

11/40 (28)

14/41 (34)

    White

21/33 (64)

22/34 (65)

    African American

Total response by race/ethnicity†

Author Manuscript

  Race

14/25 (56)

15/27 (56)

    Asian

2/3 (67)

1/3 (33)

    Mixed race or undeclared

3/7 (43)

1/2 (50)

    Hispanic/Mestizo

16/28 (57)

15/25 (60)

    Not Hispanic/Mestizo

24/40 (60)

24/41 (59)

  Ethnicity

Author Manuscript

*
Except where indicated otherwise, values are the number of patients/number evaluated (%). Values for urinary protein-to-creatinine ratio were
compared using a 2-sided t-test from an analysis of covariance (ANCOVA) model on log(urinary protein-to-creatinine ratio) that was adjusted for
log(baseline values). Values for disappearance of anti—double-stranded DNA (anti-dsDNA) antibody and lupus flares were compared using a 2sided Pearson’s chi-square test. Values for total British Isles Lupus Assessment Group (BILAG) score were compared using a 2-sided t-test from
an analysis of variance model. Values for patient’s global assessment and Short Form 36 (SF-36) were compared using actual values between
experimental and control groups and a 2-sided t-test from an ANCOVA model that adjusts for baseline values. None of the differences were
statistically significant.
†

Total response included patients in whom a complete response or a partial response was achieved.
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Table 3

Author Manuscript

Proportion of subjects with AEs through week 24*
Control
(n = 68)

Abatacept
(n = 66)

Any AE

56 (82)

56 (85)

Infection-related AEs

32 (47)

31(47)

Grade 3 or higher AEs

24 (35)

21(32)

Infection-related grade 3 or higher AEs
Serious AEs
Deaths
AEs resulting in withdrawal from study

5 (7)

8 (12)

20 (29)

19 (28)

1

0

17 (25)

11(16)

*

Values are the number (%). AE = adverse event.
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Table 4

Author Manuscript

Outcome at week 52*
Control

Abatacept

21

22

Patients with a complete response at week 24
  No. of patients
  Status at week 52
    Complete response, no. (%)

13 (62)

11 (50)

    Partial response

1

1

    Loss of renal response†

4

2

    Withdrew (nonrenal SLE flare)

0

1

    Withdrew (unrelated to SLE or abatacept)

3

7

19

17

9(47)

7(41)

    Partial response

4

6

    Loss of renal response†

5

1

    Withdrew (nonrenal SLE flare)

0

0

Patients with a partial response at week 24
  No. of patients

Author Manuscript

  Status at week 52
    Complete response, no. (%)

    Withdrew (unrelated to SLE or abatacept)
Total response at week 52, no./no. evaluated (%)‡

1

3

27/40(68)

25/39(64)

*

Except where indicated otherwise, values are the number of patients. SLE = systemic lupus erythematosus.

†

Either withdrew due to renal flare or did not meet complete response or partial response criteria at week 52.

‡

Total response included patients in whom a complete response was achieved and patients in whom a partial response was achieved.
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